WASHINGTON -- Medicare consumers with bipolar disorder or schizophrenia are hospitalized less often if they maintain access to their medications when they hit the coverage gap for prescription drugs, according to a study released today.
This has led to scientists calling for the so-called "doughnut hole" to be closed sooner than 2020, as called for in the 2010 health care law, also known as the Affordable Care Act. They would also like to see patients using more generic medications so that they can avoid hitting the gap in the first place, while saving taxpayers money. "We'd save money and have better outcomes," said Kenneth Smith, lead author of the report published in The American Journal of Managed Care. The health care law last year gave a 50% discount on name-brand drugs and a 14% discount on generics, and Smith said policymakers should consider increasing the discount on generics.
Read the full story: http://usat.ly/WMJ91Q
Source: USA Today
Trump Administration’s Message to Supreme Court Puts New Wrinkle in Braidwood Case
February 21st 2025The Trump administration argues that HHS Secretary Robert F. Kennedy Jr can overrule the US Preventive Services Task Force to determine the preventive services covered under the Affordable Care Act.
Read More
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
5 Key Health Care Moments During President Trump's First Month Back in Office
February 21st 2025President Donald J. Trump pushed for significant health care changes during his first month back in office, through executive orders affecting managed care, drug pricing, and clinical trial diversity guidance.
Read More
Same-Day Breast Imaging Gaps Reveal Health Care Disparities
February 18th 2025For this retrospective study, the authors examined data on more than 3 million screening mammographies for more than 1 million female patients; of the screenings, 23.6% had abnormal results and only 6.7% were recommended for biopsy.
Read More